Medtech Talk

Silk Road Medical CEO Erica Rogers gives an honest look back at how her past successes and failures have helped her set the course for one of Medtech’s most promising stories. Flush with capital, Silk Road is disrupting carotid artery treatment.

Jessica Traver, CEO of IntuiTap Medical, says the Texas-based start-up could solve serious but often overlooked complications of spinal punctures. The company combines imaging, analytics, and technology to help physicians place needles more safely.

Scott Dodson, president and CEO of AirXpanders, explains how the company used OUS experience and financing to get its AeroForm Tissue expander system through rigorous FDA review. The firm now is positioned to benefit from patient demand and a healthy reimbursement system.

Marie Johnson, CEO and founder of AUM Cardiovascular, lost her husband, Rob, to a heart attack. The tragedy led her to develop CADence, a handheld device that she believes will save lives by identifying telltale signs of cardiovascular disease.

George Wallace says his Intersect incubator created 13 companies over 20 years, and exited eight of them. That’s a pretty good batting average. But innovators like Wallace continue to innovate, not only with technology but also with finding new ways to create meaningful Medtech companies.

Baxter CEO Joe Almeida discusses the challenges of taking over the hospital-products maker, reshaping its culture, focusing its strategy for the future, and investing in its people.

Justin Barad talks about taking VR out of the gaming space with innovative software that will transform how orthopedic surgeons train in the OR.

Ask Endeavour Vision’s Katie Ellias what song best represents her career path to venture capital and she’d probably say, “The Long and Winding Road.” Hear how the VC established a career path that took her from Pre-Med plans to Medtronic and then Venture Capital.

Jonathan Norris of Silicon Valley Bank follows up his recent Medtech Conference presentation with insights on healthcare exits, the latest M&A chatter, the resurgence of biopharma deals, which type of Medtech start-up gets the most action, and the drastic decline in Series A device deals.

SightLine general partner Joe Biller shares his insights on the venture market, including advice for companies looking for – and working with – venture capital investors.

What steps did Boston Scientific – under Mahoney’s leadership – take to unlock such significant growth? In an interview at the Medtech Conference, Mahoney – interviewed by Kevin Hykes, CEO of Metavention - laid out some of the meaningful changes Boston Scientific made.

Serial entrepreneur Mike Berman shares how he’s seen the Medtech innovation sector evolve over the years. Times are tougher, but Berman sees reason for hope as well as concern.

This week, New Enterprise Associates – known to its friends as NEA – announced closing on a $3.3 billion venture capital fund, with roughly 10% of that total going to Medtech companies. We asked partner Justin Klein, MD, how might the $300 million or so invest in Medtech companies be deployed differently than in the prior fund.

Andrew Weiss, president & CEO of ReCor Medical, says Medtech is alive and kicking. This is an exceedingly positive statement from the CEO of a renal denervation company, an area that has been particularly hit hard. Hear his take on Medtech’s future and how Recor is making it work.

Duke Rohlen, CEO and director of Ajax Health, co-founder and CEO of Spirox Inc., explains how he’s combining his expertise, connections, and experience exiting Medtech companies with KKR’s capital to devise a new way to run start-ups.

Joe Almeida, CEO, President, and Chairman of Baxter International, Inc. joined Baxter at the beginning of 2016. He knew immediately the company needed an infusion of innovative spirit to begin to move forward.

Medtech Conference Co-Chair Kevin Hykes, who is finishing up his two-year tour of duty as a conference co-commander, reviews the agenda for next week’s Conference.

Outset CEO Leslie Trigg updates Medtech Talk listeners on her company’s bid to bring disruption to dialysis. She also shares some sage advice about what matters most in a career.

Todd Butka, the CEO and founder of Murj, personifies the much ballyhooed crossover between Medtech and Tech. The start-up is developing a software application that enables providers to efficiently manage data from implantable cardiac devices.

Paul Yock, MD, started Stanford’s Byers Center for Biodesign to help teach innovation. While the idea didn’t excite everyone, the center has emerged as the hub of entrepreneurial excellence. Dr. Yock speaks to the role of innovation and how it impacts Medtech.

Rick Randall’s initial foray into leading a Medtech company represented a bit of a fairy tale. But his next chapter – starting and leading spine company Trans1 – serves as a bit of a Medtech nightmare.

Rick Randall landed his first job in Medtech on a bet. Today, he’s one of the sector’s most experienced CEOs. In the first part of a two-part interview with Medtech Talk, Randall, the CEO of OMNIlife science, the robotic-assisted surgery company, explains how serendipity has helped guide his path into the sector.

Serial innovator Mark Blumenkranz, MD, who last year moved into an emeritus position at Stanford, shares his enthusiasm and concerns for the future of innovation in the US.

For more than a decade, Lisa Suennen, Senior Managing Director, healthcare at GE Ventures and Managing Partner at Venture Valkyrie, LLC, has blogged and opined on the healthcare industry. In this podcast she reveals what first led her to speak up and shares how Medtech execs can find their own voices. She also talks about CSweetner.org, a not-for-profit she created to help women executives rise to...

Nim Shah left Domain Associates to take on the chief business officer role at hot Start-Up Fractyl Laboratories. Hear why he made the change, what he feels went wrong for Medtech, and what’s next for Fractyl.